10 recruiting, 8 not yet recruiting, 4 completed, 3 unknown. 18 Phase 2, 9 Phase 1, 1 Not applicable, 1 Phase 3.
Follow SCLC, Extensive Stage: new trials by email Literature Review of SCLC, Extensive Stage trials Research Report on SCLC, Extensive Stage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer YL201, Serplulimab, Carboplatin - SCLC, Extensive Stage | Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 442 | 2026-08-18 | 2026-08-24 |
| Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer Toripalimab; Etoposide - SCLC, Extensive Stage, Bayesian | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 130 | 2026-08-01 | 2026-07-13 |
| Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment Lomustine, Anlotinib - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 46 | 2026-06-01 | 2026-06-08 |
| A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer benmelstobart, Anlotinib, Carboplatin or cisplatin - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 33 | 2026-04-20 | 2026-04-20 |
| Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients Biological/Vaccine: NK Cell Therapy Product Derived from Induced Pluripotent Stem Cells (iPSCs) Engineered with Anti-DLL3 CAR Construct, Followed by Differentiation and Expansion - SCLC, Extensive Stage, Neuroendocrine Tumors | Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 9 | 2026-02-20 | 2026-06-25 |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy - Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-02-02 | 2026-03-18 |
| A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy - Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2026-02-01 | 2026-07-06 |
| Anlotinib in Cross-line Treatment of NSCLC and SCLC NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage | Not yet recruiting | Henan Cancer Hospital | 350 | 2026-02-01 | 2026-02-10 | |
| Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer Toripalimab - SCLC, Extensive Stage, Toripalimab | Not yet recruiting | Fudan University | 1200 | 2026-02-01 | 2025-12-29 | |
| A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment [225Ac]Ac-DOTATATE - SCLC, Extensive Stage | Phase 1 | Recruiting | Peking University Cancer Hospital & Institute | 24 | 2026-01-20 | 2026-02-17 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors ABP1011T - SCLC, Extensive Stage, Advanced Solid Tumors | Phase 2 | Recruiting | Shanghai AB PharmaTech Ltd. | 110 | 2025-12-30 | 2026-01-07 |
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC golidocitinib with PD-1 inhibitors - SCLC, SCLC, Extensive Stage | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 20 | 2025-10-31 | 2026-02-27 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan - SCLC, SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 30 | 2025-10-22 | 2026-06-18 |
| A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC HLX10+chemo - SCLC, Extensive Stage | Phase 2 | Active not recruiting | Shanghai Henlius Biotech | 26 | 2025-06-24 | 2026-05-20 |
| Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia Nanocrystalline Megestrol Acetate, Tislelizumab, PTOC - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 250 | 2025-01-15 | 2025-01-27 |
| Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC - SCLC, Extensive Stage, Immunotherapy | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2025-01-07 | 2026-08-17 |
| A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer Arm 1, second-line group - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 70 | 2024-09-30 | 2024-10-01 |
| Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC AK104, Etoposide, Carboplatin - SCLC, Extensive Stage | Phase 1 / Phase 2 | Active not recruiting | Sichuan University | 57 | 2024-05-16 | 2026-04-29 |
| Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC Olvi-Vec, platinum (cisplatin or carboplatin), Etoposide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Recruiting | Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. | 27 | 2023-07-24 | 2025-12-03 |
Showing 20 of 27. Sign in to see all of them.
Small Cell Lung Carcinoma (7) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Disease (1) · Neuroendocrine Tumors (1) · Recurrence (1)
Neoplasms (10) · Bronchial Neoplasms (9) · Carcinoma, Bronchogenic (9) · Lung Diseases (9) · Neoplasms by Site (9) · Respiratory Tract Diseases (9) · Respiratory Tract Neoplasms (9) · Thoracic Neoplasms (9) · Lung Neoplasms (7) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1)
Carboplatin (7) · Etoposide (7) · anlotinib (6) · Cisplatin (3) · toripalimab (3) · Drug Therapy (2) · Radiotherapy (2) · Temozolomide (2) · Biological Products (1) · Chemoradiotherapy (1) · Engineering (1) · Immune Checkpoint Inhibitors (1) · Lomustine (1) · PM 01183 (1) · Platinum (1)
Henan Cancer Hospital (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Peking University Cancer Hospital & Institute (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Yayi He (2) · AIO-Studien-gGmbH (1) · Akeso (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Beijing Biotech (1) · Fudan University (1) · MediLink Therapeutics (Suzhou) Co., Ltd. (1) · Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. (1) · Peking University First Hospital (1) · Shanghai AB PharmaTech Ltd. (1) · Shanghai Henlius Biotech (1)
China (17) · Austria (2) · Germany (1) · Japan (1)
Yanqiu Zhao, MS (2) · Chunxia Su, Doctor (1) · Dingzhi Huang, Doctor (1) · Dingzhi Huang, M.D (1) · Dong Wang, PH.D (1) · Martin Reck, Prof. Dr. (1) · Ningbo Liu, Doctor (1) · Qiming Wang (1) · Richard Greil, MD (1) · Shuhang Wang, PhD (1) · Shun Lu, Professor (1) · Zhijie Wang, MD, PhD (1)